INTRODUCTION
Factor XI (FXI) is a serine protease zymogen in the intrinsic pathway related to blood coagulation ( ). The activated FXI glycoprotein 1 (FXIa) has a two-chain structure, with a heavy chain composed of four apple domains in tandem ( ) and a light chain harboring a serine 2 protease domain ( ). FXI deficiency is defined as severe when FXI Coagulation activity (FXI:C) is less than 15 U/dL and as moderate 3
when it is between 15 and 50 U/dL. The detection of patients with FXI deficiency has shifted during the last decade from clinical screening mostly identifying severe bleeders to biological screening that detects a wide range of bleeding phenotypes ( ). The gene encoding FXI (the gene) is located on the long arm of chromosome 4 (4q35) ( ) and is 50 kilobases in length, with 15 F11 7
exons. Exon 1 is non-coding; exon 2 encodes the signal peptide; exons 3 to 10 code for the four apple domains; and exons 11 to 15 encode the carboxy-terminal serine protease (SP) domain, which contains the active site.
FXI deficiency is a rare bleeding disorder that is reported in all human populations, but it is particularly common in Ashkenazi Jews (estimated carrier rate of 9.0 ) ( ), with two major mutations occurring with equal frequencies: c.403G>T (p.E135X) in exon 5, and % 8 c.901T>C (p.F301L) in exon 9 ( , ). Two mutations appear to have a higher prevalence in France: c.316C>T (p.Q106X) in the western 9 10 part of France (Nantes area) ( ) and c.166T>C (p.C56R) in Basque families in the southwest of France ( ). As of the last update of the 11 12 database, 191 mutations causing FXI deficiency had been reported, all of which are single point mutations, except for two large deletions: a 31.5 kb deletion that encompasses the entire gene ( ) and a smaller deletion that extends from exon 11 to exon 15 ( ). F11 13 14
In this study, we determined the molecular basis of FXI deficiency in 25 index patients detected based on exhibiting a FXI activity below 50 U/dL at Brest University Hospital, located in western Brittany (northwest of France). We developed, for the first time, a technique to systematically screen for rearrangements at the FXI locus in a routine setting to carry out complete direct sequencing analysis of this genomic region.
PATIENTS, MATERIALS, AND METHODS

PATIENTS
Over the course of 4 years (Jan. 2003 to Dec. 2006), 98 constitutional FXI deficiency patients were detected through a two-step biological screening strategy that combined the determination of a prolonged activated partial thromboplastin time (aPTT) with a ratio >1.2 (normal prothrombin time, normal fibrinogen and the absence of interfering heparin) followed by the detection of FXI coagulant activity (FXI:C) below 50 U/dL in the laboratory of Hematology at Brest University Hospital. The abnormal FXI:C values were confirmed in a second sample collected at a different time, and the two measurements were averaged.
Patients were recalled and forty-four patients (participation rate: 45 ) agreed to participate in this study, belonging to 25 families % living in the western Brittany area. A family tree was established for all families, and individuals were questioned about the origin of their ancestry based on the origins of their grandparents.
All 44 patients were questioned about their own bleeding history (spontaneous like epistaxis, gum bleeding, ecchymosis or related to surgical procedures) that was obtained verbally. To minimize the subjectivity of the record, 2 hematologists with expertise in hemostasis (JFA and BPP) met the patients and classified them as either bleeder or non-bleeder by each physician and blinded from the other
physician s assessment. In case of discordance the case was classified by a third clinician (PG).
'
Informed consent for molecular genetic analysis was obtained for these individuals by the referring clinician as part of our study protocol, which was approved by the local research ethics committee (CPP Ouest 6-485 and DGS 2007-0288).
Blood was obtained by venipuncture for coagulation testing and genetic analysis.
COAGULATION TEST
FXI:C was determined with an STA-evolution (Stago, Asnieres, France), using an activated partial thromboplastin time-based clotting test incorporating FXI-deficient plasma (Ref 00723;Stago). FXI antigen levels (FXI:Ag) were evaluated by an immunosorbent assay using paired polyclonal antibodies (Ref FXI-EIA; Kordia).
POINT MUTATION DETECTION
After DNA extraction from whole blood of patient s leukocytes by standard procedures ( ), screening for single point variations was 
MUTATION NOMENCLATURE
To avoid confusion related to the variants described in this study, we provide both the commonly used name found in the published literature based on the active peptide ( ) and the international nomenclature name, which is indicated between brackets in the text or 7
tables. The international mutation nomenclature is based on the guidelines of the Human Genome Variation Society ( ). cDNA-based numbering was assigned with the A of the ATG translational initiation codon being http://www.hgvs.org/mutnomen/ designated as 1 in the context of the reference sequence NM_000128.
+
POPULATION SCREENING OF THE 7 NOVEL MISSENSE MUTATIONS 3 8
To estimate the frequency of the new mutations in the general population, we set up an allele specific PCR with melting curve detection; briefly, seven primers pairs with one primer specific to each of the seven new missense mutations of the gene were mixed F11 with an internal control fragment (promotor of the gene) with the presence in the PCR of Syto9 (Invitrogen) as a fluorescent dye. HAMP The melt curve analysis (Lightscanner, Idaho Tech) allowed to discriminate between the control amplicon and the mutation specific ones.
Five hundreds controls (relatives of cystic fibrosis patients recruited through cascade screening and representing the general population of our geographic area) were screened.
SCREENING OF REARRANGEMENTS BY QUANTITATIVE FLUORESCENT MULTIPLEX PCR (QFM-PCR)
Seventeen primer pairs targeting each of the 15 exons of the gene (available upon request) and 2 amplicons upstream of the first F11 exon (promoter region), together with two control regions (exon 14 of the gene located on chromosome 11 as a diploid reference and F2 exon 8 of the gene located on the X chromosome as a quantitation control) were designed and simultaneously amplified in a single F9 reaction for systematic screening of gross rearrangements by mean of quantitative fluorescent multiplex PCR (QFM-PCR) ( ). The 17 fluorescent profiles (electropherograms) were normalized based on the peak heights of the amplicon, and the samples were then F2 superimposed upon those of a normal diploid sample. A two-fold reduction in peak height was taken as being indicative of a deletion, while a 50 increase suggested a duplication.
%
REFINEMENT OF REARRANGEMENT BOUNDARIES BY A COMBINATION OF OLIGO-ARRAY CGH AND WALKING
" "
QFM-PCR
Whole-Genome Oligoarray comparative genomic hybridization (CGH) was performed using the Human Genome CGH Microarray kit precisely localizing the centromeric breakpoint of the large telomeric deletion.
RESULTS
MOLECULAR EPIDEMIOLOGY: ALLELIC HETEROGENEITY
The strategy used in this study was to select patients based on their biological phenotypes with a prolonged aPTT and at least a 50 U/dL reduction of their FXI:C activity. Among the 25 index cases that participated in our study, thorough screening for both point mutations and rearrangements successfully identified an gene mutation in 24 individuals. As anticipated based on their FXI:C F11 phenotype ( ), 22 patients are heterozygous carriers, except for two patients who are homozygous for 2 mutations and one patient Table 1 with no mutation detected. Most of the investigated families are native of western Brittany (northwest of France), except for 5 families either of different European ancestry (from France, Germany, Italy, and Russia) or from the Middle East (Lebanon).
We observed allelic heterogeneity illustrated by 14 different single base changes identified by direct sequencing in the 23 index cases with a detected point mutation (
). Ten of the mutations are missense mutations affecting conserved amino-acids, as determined Table 1 through multiple protein sequence alignment against animal sequences. Only two mutations are nonsense mutations, one of which is located at the consensus splice site of intron 6, while one patient is a carrier of a one base deletion at position c.1565 in exon 13 resulting in a frameshift after amino acid p.Arg522. Among the 14 different mutations detected, 12 are CRM mutations (quantitative), whereas two − mutations are CRM (qualitative) ( ). Five mutations (identified in 12 families) were previously reported, whereas 9 point + Table 1 mutations (identified in 11 families) were novel. Among these 9 novel mutations, 4 are located in the serine protease domain or the active 
IDENTIFICATION of a LARGE 4q Ter DELETION
After sequencing the complete coding and flanking sequences of the gene, there were two patients remaining for whom no F11 mutation had been detected. Therefore, we developed an efficient, rapid QFM-PCR technique that included designing tag amplicons located in each of the 15 exons, allowing us, for the first time, to systematically and routinely screen the heterozygous rearrangements at the F11 locus. This strategy was found to be a success, as we were able to detect a large deletion in one patient (XXIV/41) that unexpectedly encompassed the entire gene ( ). To refine the breakpoints of the deletion, we combined array CGH ( F11 Figure 1a The most frequent mutation observed in our study (c.1789G>A, p.E597K), which was found in 5 index cases, is the first of our tag population, though it was previously reported ( ) in a single patient living in France (Paris) who does not know if his ancestors lived in 20
Brittany according to the team who reported it. The second the c.1724C>T (p.S575L) mutation, is of particular interest because in tag, addition to being original, it is the first time that a CRM mutation has been found to be recurrent (3 index cases), including one + homozygous case being observed. This study confirms the usefulness of a rare, but not private, mutation as a in a gene tag of a population involved in a rare Mendelian disease.
The Basque mutation (c.166T>C) was also found in 3 index cases, (same haplotype with the original 12 repeats at marker CAi3(B) rs72428153, data not shown), representing a mutation shared between our study population and the Basques. The economic links tag (fishermen) between the Basques and Britons during the last centuries are documented in French religious records (available upon request). However classical population genetics studies using mtDNA ( ) have failed to connect these two populations at the genetic c.166T>C mutation remains unknown because, as in the Basque population ( ), we did not find CAi3-12 repeats allele among 100 12 healthy controls, which may indicate that the mutation originated in another population that migrated to the western part of continental Europe. After the first step of the strategy for mutation detection developed in this study, consisting of screening for point mutations in the 15 exons of the gene, no mutation had been detected in 2 patients among the 25 index cases.
F11
Based on the accumulation of data during the last decade, it is now possible to systematically complete the mutation detection process by screening for large rearrangements. In one of the two patients lacking mutations, we suspected the occurrence of this type of large deletion based on a transmission discrepancy at rs5969 in exon 7, suggesting hemizygosity at this location. The second justification for screening for genomic events was that two gene deletions had been previously reported: a 31.5 kb deletion was found using an EBV-F11 transformed cell assay converting to haploid chromosomes ( ), and the exons 11-15 del was detected in a homozygous carrier from 13
Tunisia through the failure of PCR amplification of these five exons ( ). Based on this information, we decided to develop, for the first 22
time, a systematic strategy for screening for heterozygous rearrangements at the F11 locus by quantitative multiplex PCR. This method is inexpensive and robust, and thus, can be performed routinely. Using this strategy, we successfully identified a 7 Mb heterozygous deletion at 4qter.
We postulate that our method of patient selection based on aPTT, which corresponds to a mild phenotype, explains why we mostly found heterozygous carriers (21/23). The exhaustive mutation detection strategy used in this study (for point mutations and rearrangements) failed to identify the mutational status in only one patient among the 25 individuals studied, which is concordant with the results of previous studies ( ). Our analyses were focused on the exonic and flanking sequences of the gene, thus missing any 16 F11 nucleotide variation located in intron or promoter sequences or even in other putative genes resulting in FXI deficiency. Some types of mutations, such as large inversions, remain undetected by the techniques used. It can be observed that the FXI levels of patient XXV/44 are only at the threshold for FXI deficiency, but they were confirmed in two samples, and thus, we kept him in the cohort. In the perspective of a routine diagnostic analysis, describing the molecular epidemiology allows to optimize the strategy by targeting the exons carrying most of the mutations : in our population, 50 of the mutated alleles (12/24) are located in only 2 exons (i.e. exons 3 and 15).
%
The combination of arrayCGH ( ) and walking QFM-PCR was very efficient for delineating the loss of 4q telomeric Figure 1b " " sequences. However, based on the pauci-symptomatic phenotype of the patient and her children, the discovery of such a large deletion (~7 Mb) was unexpected. In 1999, Tsai & al ( ) reported a 4q34.2 telomeric deletion in a child, identified by FISH, associated with 23 velocardiofacial syndrome. Other cases of 4q deletion are described in the literature, with a phenotypic spectrum ranging from asymptomatic ( ) to a polymalformative syndrome ( ) or mental retardation ( ). Based on physical examination, patients from family 24 25 26 XXIV (a mother and two children) do not exhibit any cardiac abnormalities, facial dysmorphy or evident mental retardation; their only particular phenotype appears to be a FXI deficiency.
These findings highlight the importance of screening for large heterozygous deletions in molecular studies of F11.
What is known on this topic 
